drugset
Drugs / Mavrilimumab
last change Mar 2022 re-read 2 minutes ago

Mavrilimumab

also known as CAM-3001 · KPL-301

Monoclonal antibody

Developed for
rheumatoid arthritis · COVID-19 · acute respiratory distress syndrome · pneumonia · temporal arteritis · viral pneumonia
Investigated by
MedImmune LLC · Kiniksa Pharmaceuticals, Ltd. · Kristin Hudock · Ospedale San Raffaele

Trials 8 · a red edge is where a trial was stopped

today NCT04397497 · Ph 2 NCT04492514 · Ph 2 NCT03827018 · Ph 2 NCT02213315 · Ph 1 NCT01715896 · Ph 2 NCT01712399 · Ph 2 NCT01706926 · Ph 2 NCT01050998 · Ph 2
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT02213315 Jul → Dec 2014 — MedImmune LLC Completed No outcome recorded
Phase 27 trials
Phase 2 NCT04397497 May → Sep 2020 COVID-19, acute respiratory distress syndrome, viral pneumonia Ospedale San Raffaele Unknown No outcome recorded
Phase 2 NCT04492514 May → Nov 2020 COVID-19, pneumonia Kristin Hudock Completed No outcome recorded
Phase 2 NCT03827018 Sep 2018 → Aug 2020 temporal arteritis Kiniksa Pharmaceuticals, Ltd. Completed No outcome recorded
Phase 2 NCT01715896 Mar 2013 → Nov 2014 rheumatoid arthritis MedImmune LLC Completed No outcome recorded
Phase 2 NCT01712399 Jan 2013 → Dec 2015 rheumatoid arthritis MedImmune LLC Terminated No outcome recorded
Phase 2 NCT01706926 Aug 2012 → Dec 2013 rheumatoid arthritis MedImmune LLC Completed No outcome recorded
Phase 2 NCT01050998 Jan 2010 → Jun 2011 rheumatoid arthritis MedImmune LLC Completed No outcome recorded
Also used as a comparator or background therapy in 4 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00771420 Comparator Oct → Dec 2008 rheumatoid arthritis MedImmune LLC Completed No outcome recorded
Phase 22 trials
Phase 2 NCT04463004 Comparator Sep → Nov 2020 COVID-19, pneumonia Virginia Commonwealth University Completed No outcome recorded
Phase 2 NCT04399980 Comparator May 2020 → Apr 2021 COVID-19, pneumonia The Cleveland Clinic Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT04447469 Comparator Jul 2020 → Nov 2021 COVID-19 Kiniksa Pharmaceuticals International, plc Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 15 sources stand behind the page.

FieldValueCited text
Known as Mavrilimumab ClinicalTrials.gov intervention name — accepted as the source's own label NCT04492514 ↗
10

NCT02213315 ↗

NCT01715896 ↗

NCT04397497 ↗

NCT01706926 ↗

NCT01050998 ↗

NCT04399980 ↗

NCT03827018 ↗

NCT04463004 ↗

NCT01712399 ↗

NCT04447469 ↗
Known as CAM-3001 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00771420 ↗
Known as KPL-301 ChEMBL registry synonym — accepted as the source's own label CHEMBL1743039 ↗
Action Inhibit “We evaluated the efficacy of the GM-CSF receptor antagonist mavrilimumab in maintaining disease remission.” PMID 35264321 ↗ Mar 2022
Modality Monoclonal antibody “Mavrilimumab, a fully human monoclonal antibody targeting the granulocyte-macrophage colony-stimulating factor receptor-α” PMID 28213566 ↗ Feb 2017
Route Subcutaneous “injection subcutaneously” NCT01050998 ↗